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Abstract
Hepatitis C virus (HCV) is a major cause of chronic liver diseases including steatosis, cirrhosis and hepatocellular
carcinoma. Currently, there is no vaccine available for prevention of HCV infection due to high degree of strain
variation. The current treatment of care, Pegylated interferon a in combination with ribavirin is costly, has
significant side effects and fails to cure about half of all infections. The development of in-vitro models such as
HCV infection system, HCV sub-genomic replicon, HCV producing pseudoparticles (HCVpp) and infectious HCV
virion provide an important tool to develop new antiviral drugs of different targets against HCV. These models also
play an important role to study virus lifecycle such as virus entry, endocytosis, replication, release and HCV induced
pathogenesis. This review summarizes the most important in-vitro models currently used to study future HCV
research as well as drug design.
Introduction
HCV infection is a serious global health problem that
affects 180 million people worldwide and 10 million peo-
ple in Pakistan [1]. It is estimated that three to four million
people are infected with HCV every year. HCV causes
acute and chronic hepatitis which can eventually lead to
permanent liver damage and hepatocellular carcinoma [2].
Of those acutely infected with HCV, around 85% develop
chronic infection. Approximately 70% of patients with
chronic viremia develop chronic liver disease, 10-20% of
which develop liver cirrhosis. Hundreds of thousands of
people die each year from liver failure and liver cancer
caused by this disease.
HCV is a small enveloped virus with a positive sense,
single-stranded RNA genome that encodes a large poly-
protein of 3010 amino acids. The polyprotein is co- and
posttranslationally processed by cellular and virally
encoded proteases to produce four structural (Core, E1,
E2 and P7) and six non-structural (NS2, NS3, NS4A,
NS4B, NS5A, NS5B) proteins [3,4]. Among the structural
protein, HCV envelop protein E1 and E2 are highly glyco-
sylated and play an important part in cell entry. HCV NS3
serine protease and NS5b play an important role in repli-
cation. HCV NS3 serine protease, NS5B RNA-dependent
RNA polymerase and HCV structural proteins are impor-
tant targets for antiviral drug development (Figure 1).
On the basis of nucleotide variation HCV is divided
into six major genotypes and more than 80 subtypes.
There is 30-50% variation among viral genotypes and
15-30% among different subtypes while there is 1-5%
variation in nucleotide sequence from a single HCV
infected patient [5,6]. They occur in different proportion
in different parts of the world. Genotype 1a and 1b are
the most common genotypes in the United States and
Europe [7,8]. The most prevalent HCV genotype in
Pakistan is 3a followed by 3b and 1a [9].
Presently, there is no vaccine available for prevention of
HCV infection due to high degree of strain variation.
Current therapeutic options for hepatitis C are limited,
especially for genotype 1. For genotypes 2 and 3, pegy-
lated interferon in combination with ribavirin, can lead
to a sustained virological response in up to 80% of
patients [10]. However, the therapy is expensive and
often associated with side effects that may lead to discon-
tinuation of therapy [11]. Hemolytic anemia, cough,
shortness of breath & treatogenicity are the most com-
mon adverse effect associated with ribavirin treatment,
and muscle aches, fatigue & neuropsychiatric adverse
effects of IFN-a lead to premature cessation of therapy in
10 to 20% of patients [12,13]. Moreover, cost of inter-
feron for 6 month treatment ranging from PKR 50,000 to
150,000 is beyond the financial range of most patients.
Hence, there is need to develop anti HCV agents, both
from herbal sources and synthetic chemistry which are
less toxic, more efficacious and cost-effective. In this
review, we summarizes the most important in-vitro
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HCV Infection System
In the past, research into HCV has been hampered due to
lack of a reliable cell culture system. Conventional virolo-
gical methods failed to initiate productive HCV infection.
With the passage of time, new molecular techniques made
it possible to develop an efficient in-vitro culture system to
facilitate the study of HCV. Initial attempts to established
HCV infection used primary cells from humans and chim-
panzees. Primary human foetal hepatocytes infected with
HCV-containing sera detected the positive strand of virus
but the replication is low [14]. Human fetal hepatocytes
supported HCV replication after infection with patient
sera of 1a, 1b, 2a, 2b, and 3 HCV genotypes. HCV infected
hepatocytes released HCV into medium for at least 2
month and HCV core protein and HCV negative-strand
RNA also detected in infective cells. Viral replication had
some cytotoxic effects on the cells due to production of
interferon as a component of the antiviral response [15].
D u et os h o r tp a s s a g el i f ea n dcontamination problems
in primary hepatocytes, scientists tried to develop
immortalized human hepatoma cell lines. Many cell lines
supported HCV infection and replication in-vitro such as
Human T-lymphocyte cell lines, human fibroblast cells
(VH3), peripheral blood mononuclear cells (PBMCs) and
hepatocytes. But, hepatocytes are the target cells for
HCV replication. Hepatoma cell line 7721 is susceptible
to HCV by incubation of cells with HCV infected serum.
HCV RNA is detected for at least three months following
infection. This result also suggested that if the HCV-
infected hepatoma cells were co culture with PBMCs,
they were able to transfer the virus into PBMCs [16].
A human hepatocyte cell line, PH5CH, which is immor-
talised with simian virus 40 large antigen, was extensively
studied. Although found to be more susceptible to HCV
infection than others, the system was still inefficient [17].
Studies looking at hepatoma cell lines HepG2 and HuH-7
gave poor results even though conditions were changed
extensively to try to optimise the approach [18,19]. Mizu-
tani looked at infection of the human T-cell line, MT-2,
which harbours human T-cell leukaemia virus-1 (HTLV-1).
Although susceptible to HCV infection, it was not possible
to produce long-term infection. Infection of Daudi cells, a
B-lymphoplastoid cell line, managed to produce long-term
infection for up to 1 year [20] but addition of the virus
led to cellular cytopathic affects. It was possible to infect a
chimpanzee with supernatant obtained after 58 days of
culturing in Daudi cells, but infectivity was low. Other
attempts were made to culture virus directly from cells of
infected liver biopsies from persistently infected patients
[21]. However, replication efficiency was low and reprodu-
cibility of the system was poor.
HCV sub-genomic replicon
The HCV replicon system replicates a modified HCV
genome to high levels in human hepatoma (Huh-7)
Figure 1 Proteins encoded by the HCV genome. HCV is formed by an enveloped particle harbouring a plus-strand RNA of ~9.6 kb. The
genome carries a long openreading frame (ORF) encoding a polyprotein precursor of 3010 amino acids. Translation of the HCV ORF is directed
via a 340 nucleotide long 5’ nontranslated region (NTR) functioning as an internal ribosome entry site; it permits the direct binding of ribosomes
in close proximity to the start codon of the ORF. The HCV polyprotein is cleaved co- and post-translationally by cellular and viral proteases into
ten different products, with the structural proteins (core (C), E1 and E2) located in the N-terminal third and the nonstructural (NS2-5) replicative
proteins in the remainder. Putative functions of the cleavage products are shown [4].
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ing only the non-structural proteins for RNA replica-
tion) or genomic in length (contains the entire HCV
genome). Both types of replicons contain the neomycin
phosphotransferase gene for selection. A bi-cistronic
replicon was created with the inclusion of an encephalo-
myocarditis virus (EMCV) IRES before the HCV non-
structural genes. All genes are driven by a T7 promoter.
Following transcription with T7 RNA polymerase, repli-
con RNA is transfected into Huh-7 human hepatoma
cells. RNA replication allows cells to grow and
form colonies in the presence of the antibiotic G418
(Figure 2).
Some Replicons containing a luciferase gene to replace
the neomycin phosphotransferase gene were used in
transient assays to identify adaptive mutations. The
replicon acquired adaptive mutations by unknown
mechanism. Adaptive mutations are generally detected
in NS3, NS5A and NS5B proteins [22,24]. Adaptive
mutation in NS5A region causes interferon resistance.
The highly adapted 5.1 replicon contained three adap-
tive mutations (two in NS3 and one in NS5A). These
adaptive mutation strongly increase RNA replication
[25].
A full-length clone bearing three adaptive mutations
was not infectious to chimpanzees, while a clone bearing
one adaptive mutation could infect and this mutation
reverted back to wild-type [26]. Cellular factors were
also important for replicon establishment in cell culture.
Replicons of passage number 128 replicated 100-fold
more efficiently than those in cells at passage number
15 [24]. Characterization of cells that harbored replicons
showed that they were able to maintain autonomously
replicating RNA for over one year. Furthermore, viral
RNA was still detectable 10 months after removal of
selection by neomycin. Replicon-bearing cells showed
no obvious signs of cytopathogenicity. Viral proteins
were localized to ER membranes and replication and
expression were linked to the cell cycle [27]. Long term
treatment of replicon-harboring cells with IFN-a effec-
tively removed or “cured” cells of the replicon [28]. Sub-
genomic replicons, have been extremely useful for the
screening of chemical libraries for novel molecules with
antiviral actions against HCV.
Infectious HCV virion
Recent studies have led to the development of infectious
HCV culture systems. Wakita and his colleague developed
genotype 2a full length replicon (JFH-1) which was iso-
l a t e df r o maJ a p a n e s ep a t i e n t with fulminant hepatitis.
This HCV full length genome replicates efficiently and
produce virus particle (HCVcc) in Huh- 7 [29]. Chimaeric
constructs of JFH-1 with the structural region of the J6
genotype 2a clone improved the infectivity [30].
Further refinements have led to the development of
Huh7 derived cell lines (Huh7.5.1) which result in
increase the viral titer 10
4 -1 0
5 infectious units per ml
of culture supernatant and these cell lines are highly
Figure 2 The HCV subgenomic replicon system.
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tious particle is an ideal tool to study all aspects of the
HCV life cycle including viral attachment, entry, traf-
ficking, replication. Virus particles can be neutralized
with CD81 antibody and monoclonal antibody against
the viral glycoprotein E1 and E2 [32]. HCVcc replication
can also be inhibited by interferon-alpha and by several
HCV-specific antiviral compounds, suggesting JFH-1
infectious culture system, is a powerful tool to study
antiviral drugs and vaccines. But, there are some limita-
tion to use JFHI infectious particles such as these parti-
cles isolated from Fulminent Hepatitis which is rare
event in hepatitis. Another important limitation that
HCV particles is based on genotype 2 which is not
dominant genotype in world and Pakistan.
HCV producing Pseudo particle (HCVpp)
HCV pseudotype particles were produced to study the
early stages of viral life cycle. HCVpp were produced by
transfecting the three vectors in Human embryo kidney
cells (293T). The first vector encodes retroviral Gag and
Pol proteins which are responsible for particle budding
a tt h ep l a s m am e m b r a n ea n dR N Ae n c a p s i d a t i o n .T h e
second vector encodes a reporter protein (Luciferase) or
GFP. The third vector encodes HCV glycoproteins E1
and E2, which are necessary for viral tropism and fusion
of HCV pseudo type particles with target cell mem-
brane. 293T cells secreted virus pseudo particle an aver-
age 10
5 particles/ml, which can be used to infect Huh
7 cells and infectivity is eveluated by quantification of
amount of luciferase or GFP expressed in Huh-7 cells.
These virus like particles can be neutralized with mono-
clonal antibody against the viral glycoprotein E1, E2 and
sera of HCV infected patient [32,33] and are a powerful
tool to identify inhibitors which block HCV entry.
HCVpp are also essential to find out fusion mechanism
of virus (Figure 3).
Conclusion
HCV infection is a serious global health problem neces-
sitating effective treatment. Currently, there is no
vaccine available for prevention of HCV infection due to
Figure 3 Scheme of HCVpp production and infection. HEK-293T cells were transfected with CMV-Gag-Pol, Luciferase vector and HCV GP
expression constructs. Successfully transfected 293T cells assemble HCVpp intracellularly and secrete them into the supernatant. The HCVpp-
containing supernatant can be harvested. The supernatant can then either be used unmodified or conditioned (centrifugation, drug treatement
etc.) to infect target cells. HCVpp attach to the target cells, become endocytosed and fuse with the endocytic membranes to release the
retroviral core containing the luciferase vector into the cytoplasm. The Luciferase vector is then reverse transcribed and integrated into the host-
cell genome. 24 to 96 hours after infection, transgene expression can be analyzed.
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standard, Pegylated interferon a in combination with
ribavirin is costly, has significant side effects and fails to
cure about half of all infections. The development of
robust, cell-based replication and entry systems such as
HCV sub genomic replicons, HCVpp and Cell culture
producing virion will certainly accelerate the anti-HCV
drug development process. With determination and
innovation, we will undoubtedly meet the medical needs
of those chronically infected with HCV.
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